Gene Therapy On Cardiovascular Disease Market
Gene Therapy On Cardiovascular Disease Market
Scope: Industry Analysis, Market Size, Growth,
Trends Till 2031
Request Sample Report
Gene Therapy On Cardiovascular Disease Market Size and Growth
The Gene Therapy on Cardiovascular Disease market is witnessing significant growth, driven by advancements in genetic engineering and increasing prevalence of cardiovascular disorders. Market size is projected to reach approximately $2 billion by 2025, fueled by rising investment in research, innovative therapy developments, and favorable regulatory policies enhancing treatment availability and accessibility.
Companies Covered
(Covid 19 Impact Covered)
◍ Biogen
◍ Novartis
◍ Gilead Sciences
◍ Sarepta Therapeutics
◍ Alnylam Pharmaceuticals
◍ Amgen
◍ Spark Therapeutics
◍ Akcea Therapeutics
◍ bluebird bio
◍ Sunway Biotech
◍ SIBIONO
◍ AnGes
◍ Orchard Therapeutics
◍ Human Stem Cells Institute
The gene therapy market for cardiovascular diseases features companies like Biogen, Novartis, and Gilead Sciences. These firms invest in innovative gene therapies to target cardiovascular conditions, enhancing treatment efficacy. Their contributions drive growth through clinical advancements and expanding product pipelines. Selected revenue figures include:
- Biogen: $8.1 billion
- Novartis: $51.6 billion
- Gilead Sciences: $26.1 billion Request Sample Report
Market Segmentation
By Application
Heart Disease
Vascular Disease
Request Sample Report
By Product
Viral Gene Therapy
Non-Viral Gene Therapy
Market Growth
Request Sample Report
$ X Billion USD
